Followers | 144 |
Posts | 27603 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
![](https://investorshub.advfn.com/uicon/33650.png?cb=1628859195)
Wednesday, July 20, 2005 11:50:33 AM
U.S. Venture Partners eyes Israel hi-tech firms
Wed Jul 20, 2005 11:38 AM ET
By Steven Scheer
TEL AVIV, July 20 (Reuters) - U.S. Venture Partners (USVP) plans to invest in a number of Israeli high-tech start-ups using some of the $600 million in its latest venture capital fund, a USVP general partner said on Wednesday.
"Of the $600 million, we expect a meaningful percentage -- a double digit percentage -- allocated to Israel," Chris Rust told reporters during a visit to Tel Aviv. "We have 18 to 20 active (Israeli) investment proposals ... and I am sure some of those will crossover."
He said USVP is particularly focused on early-stage funding for companies in life sciences, medical devices, semiconductors, software, clean technology, security and telecommunications, sectors heavily represented in Israel. Rust said California-based USVP targets companies with the potential to go public.
Overall, USVP's ninth fund since its establishment in 1981 aims to comprise 55 to 65 companies, mostly in Silicon Valley and Israel, said Rust, noting an average financing round is $4 million, with $8 million the most it invests at one time. It often invests with other funds.
He noted that over the past 24 years, USVP has invested $2.5 billion in high-tech companies, usually taking a 20 to 30 percent stake.
USVP has invested $100 million in Israeli companies over the last decade, including early stage funding in Check Point Software Technologies (CHKP.O: Quote, Profile, Research) and Compugen (CGEN.O: Quote, Profile, Research) .
In recent years, USVP has invested in Dotomi, an Internet advertising management firm, as well as chip maker Mellanox, software maker Imperva and broadband access systems maker Actelis.
"We are drawn to Israel; it has tremendous resources on the people side," Rust said, downplaying an often troublesome security environment, particularly over the past five years of Palestinian-Israeli violence.
"We take a long-term view," he said. "We are not deterred from investing in Israel ... These are issues the whole world is grappling with. Israelis are resilient and productive even when faced with these complexities."
He pointed to similarities between the cultures of the U.S. and Israel, as well as a democratic political system and free markets.
Rust said that although many funds were shifting their focus to hot-spots like China and India, USVP does not plan on significant investments there, despite the fact that China produces more engineer graduates than the rest of the world.
"We expect there to be continued globalisation and competition to the United States and Israel from emerging markets like India and China," he said.
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh17920_2005-07-20_15-38-08_l20....
Dubi
Recent CGEN News
- Compugen to Present at Upcoming Antibody Industrial Symposium • PR Newswire (US) • 06/17/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 11:00:12 AM
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig • PR Newswire (US) • 05/30/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2024 11:00:07 AM
- Compugen Reports First Quarter 2024 Results • PR Newswire (US) • 05/20/2024 11:00:00 AM
- U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip • IH Market News • 05/20/2024 10:59:35 AM
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:02:08 AM
- Compugen Appoints David Silberman as Chief Financial Officer • PR Newswire (US) • 05/15/2024 11:00:00 AM
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 • PR Newswire (US) • 05/06/2024 11:00:00 AM
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 • PR Newswire (US) • 04/10/2024 11:00:00 AM
- Compugen to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy • PR Newswire (US) • 03/11/2024 11:00:00 AM
- Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 • PR Newswire (US) • 03/06/2024 12:00:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:06:21 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:00:24 PM
- Compugen Reports Fourth Quarter and Full Year 2023 Results • PR Newswire (US) • 03/05/2024 12:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 • PR Newswire (US) • 02/26/2024 12:00:00 PM
- Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 • PR Newswire (US) • 02/20/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 12:00:08 PM
- Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer • PR Newswire (US) • 02/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:10:06 PM
- Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer • PR Newswire (US) • 01/08/2024 12:05:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM